Clinical trials: Umbilical Cord Mesenchymal Stem Cells
Keloid
Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid
The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020.
- Trial name
- Keloid (NCT04326959)
- Testing
- Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium, Conditioned Medium, Triamcinolone Acetonide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PT. Prodia Stem Cell Indonesia
Rheumatoid Arthritis
Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis
Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis will eventually result in the destruction of cartilage, bone and ligaments and joint…
- Trial name
- RA (NCT01547091)
- Testing
- Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs), Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs), UC-MSC+DMARDS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Alliancells Bioscience Corporation Limited
Duchenne Muscular Dystrophy
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD), an X-linked recessive genetic disease always progressed slowly，tends to leading proximal skeletal muscle atrophy and weakness of limbs, as well as impaired respiratory muscle and cardiac muscle.
- Trial name
- NCT01610440
- Testing
- human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Cerebral Hemorrhage
Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela
The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for cerebral hemorrhage sequela.
- Trial name
- NCT02283879
- Testing
- Human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Acute Leukemia
Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and…
- Trial name
- NCT00823316
- Testing
- Human umbilical cord blood-derived mesenchymal stem cells
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Medipost Co Ltd.
Acute Respiratory Distress Syndrome
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome
Primary Objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Secondary Objectives: To explore the…
- Trial name
- ARDS (NCT07413978)
- Testing
- 1 vial containing a total of 5×10^7 cells, 2 vial containing a total of 1×10^8 cells, 3 vial containing a total of 1.5×10^8 cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changchun Tuohua Pharmaceutical Co., Ltd.
Heart Failure
The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)
The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating heart failure patients
- Trial name
- NCT03180450
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Retinitis Pigmentosa
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells.
- Trial name
- NCT05909488
- Testing
- 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Parkinson's Disease
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease
This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem Cells transplantation in Parkinson's disease.
- Trial name
- NCT03550183
- Testing
- mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Newtherapy BIo-Pharma technology Co., Ltd.
Crohn's Disease
Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with moderately active Crohn's disease after injection for 28days.
- Trial name
- NCT02000362
- Testing
- Stem cells
- Where
- 7 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Cartilage Diseases, Osteoarthritis
Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect
The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for articular cartilage defect of knee.
- Trial name
- NCT02291926
- Testing
- Human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Degeneration Articular Cartilage Knee
Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects
The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
- Trial name
- NCT01733186
- Testing
- CARTISTEM®
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Medipost, Inc.
Osteoarthritis
The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis
This study aims to study the safety and efficacy of XytriX, an umbilical cord-derived stem cell product, in the treatment of Grade I-IV knee osteoarthritis.
- Trial name
- NCT07487766
- Testing
- Mesenchymal Stem Cell Injection
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- TricelX Inc.
ST Elevation Myocardial Infarction
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI .
- Trial name
- NCT06147986
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Control group
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Ankylosing Spondylitis
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy…
- Trial name
- NCT05962762
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Knee Osteoarthritis
Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis
This clinical trial is performed with patients with knee osteoarthritis who were radiologically diagnosed with Kellgren-Lawrence (K\&L) grade 2 or 3.
- Trial name
- NCT04037345
- Testing
- SMUP-IA-01(low-dose), SMUP-IA-01(mid-dose), SMUP-IA-01(high-dose)
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Medipost Co Ltd.
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes.
- Trial name
- NCT05387278
- Testing
- EV-Pure™ and WJ-Pure™
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vitti Labs, LLC
Premature Ovarian Failure，
Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure
Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40.
- Trial name
- NCT01742533
- Testing
- human umbilical cord mesenchymal stem cells, hUCMSCs and hCBMNCs, human cord blood mononuclear cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Left Ventricular Dysfunction, Acute Myocardial Infarction
UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation
- Trial name
- NCT03902067
- Testing
- UC-MSC, Control Group
- Where
- China
- Sponsor
- Shanghai Life Science & Technology
Autism
Safety and Efficacy of Stem Cell Therapy in Patients With Autism
Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic…
- Trial name
- NCT01343511
- Testing
- human cord blood mononuclear cells, human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.